TMDX— AI Stock Forecast & Price Targets
Published 6/29/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live TMDX price forecast →
TransMedics has the rare combination of 30% top-line growth, 27% net margins and 45% ROE, but the stock has been cut nearly in half YTD (-43.7%) on Stifel's cautious note and a $722K insider sale, leaving it at ~$68 vs. analyst targets near $119. The fundamentals remain compelling for a category-defining medical device platform, but Q1 2026 showed clear margin compression and FCF turned negative, so this is a high-conviction-but-volatile setup that warrants accumulation rather than chasing.
1-4 weeks: Cautious — do not chase the model's 1d bullish forecast given its sub-baseline accuracy. Wait for either (a) a reclaim of $77-78 with volume to confirm the Stifel-driven flush is over, or (b) a flush to $60-62 (52w low retest) for a higher-quality entry. Starter position (¼ size) acceptable here at $68 given the asymmetric analyst target ($119 consensus). Invalidation: weekly close below $60.
1-6 months: Constructive into the next earnings print, which will either confirm the Q1 margin compression as a one-off (debt raise to fund expansion) or validate Stifel's caution. Base case return to $90-100 (+30-45%) if margins stabilize and revenue growth holds ~25%+. Catalysts: earnings, any management commentary on the debt raise, OCS Liver utilization data. Mind-changer: a second quarter of operating margin <10% and negative FCF.
1-3 years: TMDX remains the only commercial-scale organ-care platform with a turnkey logistics + device + service model — a genuine category creator in heart, lung and liver transplant. If they can return to 20%+ operating margins on a $1B+ revenue base, the stock supports $150-200+. Biggest structural risk is competitive entry (XVIVO, normothermic perfusion peers) combined with the now-leveraged balance sheet (debt/equity 1.75) reducing the margin for execution error.
Revenue trajectory remains healthy with TTM sales of $635.9M (+30.2% Y/Y) and Q1 2026 revenue of $173.9M up sequentially from $160.8M in Q4 2025, but the quality of earnings is deteriorating: operating margin compressed from 23.2% in Q2 2025 to just 7.6% in Q1 2026, and EPS Q/Q is -71%. Gross margin has slipped from 61.4% to 58.2% over the same window. Free cash flow turned negative in Q1 2026 (-$12.1M) after three strong quarters, driven by capex stepping up to $36.7M, while total debt ballooned from $519M to $863M in a single quarter — a major balance sheet event that needs explanation. Offsetting this, the company still carries $461.7M cash, a 6.74 current ratio, 45.2% ROE, 27% profit margin and trades at only 15.7x trailing P/E and 3.7x P/S — cheap for a medtech compounder if growth re-accelerates. PEG of 1947 is essentially meaningless given the forward EPS reset, but forward P/E of ~19-21x is reasonable.
Across all timeframes the trend is decisively broken. The 1d chart shows TMDX collapsing from ~$150 in March to $68.44, sitting -40% below SMA200, -15% below SMA50, and -6% below SMA20 — a textbook downtrend with price near the 52-week low of $60.10. RSI of 40 is weak but not yet oversold. The 1h chart captures the violent ~$78 → $68 capitulation candle around June 25 on the Stifel/insider sale news. Crucially, the Kronos forecast band is bullish on 1h and 4h (projecting $82-$153) but the model's own realized 1d directional accuracy is only 36% vs. a 64% naive baseline, so the short-term bullish forecast must be heavily discounted. The 1wk forecast is more measured ($96 target). Key support: $60 (52w low) then air pocket. Key resistance: $77-78 (breakdown shelf), then $90, then $103-105 SMA50 zone.
The actionable news is squarely bearish in the near-term: Stifel maintained a Hold with a $80 PT (June 18) and an insider sold $722K of stock (June 24), which together appear to have triggered the ~12% single-day drop visible on the 1h chart. Management has reportedly rebutted Stifel's commentary but has not issued a formal public statement, leaving an information vacuum into the May 5 earnings print (per snapshot data — date appears stale, next earnings is the key catalyst). The Simply Wall St. piece (June 6) reinforces the bull case around the OCS platform's role in transforming organ transplant economics, which remains the structural thesis. Crypto/macro headlines in the broader feed are irrelevant to TMDX.
- OCS Liver ramp — the newest of the three modalities (heart/lung/liver) and the largest TAM expansion vector
- National OCS Program turnkey outsourcing — the aviation/logistics layer drove the 86% 3Y sales CAGR and continues to scale
- DCD (donation-after-circulatory-death) heart adoption — expands the donor pool that cold storage cannot serve
- Q1 2026 debt raise to ~$863M total debt suggests a step-up in capacity investment (capex jumped to $36.7M) ahead of volume growth
- International expansion outside the US (per company description) — currently a small revenue contributor
- Operating margin collapsed from 23.2% (Q2'25) to 7.6% (Q1'26) — if this is structural and not investment-driven, the entire bull thesis breaks
- Total debt nearly doubled in one quarter ($519M→$863M) with debt/equity now 1.75, reducing financial flexibility
- Free cash flow turned negative in Q1 2026 after a strong 2025 — a trend to watch
- Short interest at 23% of float (6x days-to-cover) signals the bears have conviction and could amplify any earnings miss
- Stifel's cautious stance is unresolved publicly and creates an overhang into earnings
- Insider selling ($722K) during a drawdown is a negative signal even if small in dollar terms
- Stock is -47% over the past year and -40% below SMA200 — momentum is decisively broken; value traps in medtech can persist for quarters
- Kronos 1d model has been beaten by the naive baseline (36% vs 64%) — its bullish near-term forecast is unreliable
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord